Formulation, Evaluation Of Combination Of Rabeprazole And Baclofen Bilayer Tablet For The Treatment Of Gastroesophageal Reflux Disease (Gerd)
Keywords:
GERD, Rabeprazole Sodium, Baclofen, Bilayer Tablet, Immediate and sustained release layer, In-vitro evaluation and Controlled release formulationAbstract
Gastroesophageal Reflux Disease (GERD) is a chronic condition characterized by the reflux of gastric contents into the esophagus, often requiring both acid suppression and control of lower esophageal sphincter relaxation. The present study focuses on the formulation and evaluation of a bilayer tablet containing Rabeprazole in the immediate-release layer and Baclofen in the sustained-release layer to provide dual-phase therapeutic action. Rabeprazole offers rapid proton pump inhibition, while Baclofen, a GABA-B agonist, reduces reflux episodes by decreasing transient lower esophageal sphincter relaxations.
The bilayer tablets were formulated using appropriate polymers and excipients, optimized through preformulation studies, and evaluated for weight variation, hardness, friability, drug content, disintegration time, and in-vitro drug release. Results showed satisfactory physicochemical properties, effective separation of release profiles, and promising sustained action. The bilayer design significantly enhances patient compliance by combining two therapeutic approaches into a single dosage form, offering potential for improved clinical outcomes in GERD management
Downloads
Metrics
References
Article (Kasugai2024) Kasugai, Kunio / Ogasawara, Naotaka Gastroesophageal reflux disease: Pathophysiology and new treatment trends 2024 Internal Medicine , Vol. 63, No. 1 The Japanese Society of Internal Medicine p. 1-10
Article (Dent1998) Dent, J. / Brun, J. / Fendrick, A. M. / Fennerty, M. B. / Janssens, J. / Kahrilas, P. J. / Lauritsen, Karsten / Reynolds, J. C. / Shaw, M. / Talley, N. J. An evidence-based appraisal of reflux disease management—the Genval WorkshopReport 1998 Gut , Vol. 44, No. suppl 2 BMJ Publishing Group p. S1-S16
Article (Patrick2011) Patrick, Lyn Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. 2011 Alternative Medicine Review , Vol. 16, No. 2.
Article (Vakil2006) Vakil, Nimish / Van Zanten, Sander V. / Kahrilas, Peter / Dent, John / Jones, Roger / Group, Global Consensus / others The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus 2006 Official journal of the American College of Gastroenterology| ACG , Vol. 101, No. 8 LWW p. 1900-1920
Article (Zajac2013) Zajac, Peter / Holbrook, Abigail / Super, Maria E. / Vogt, Manuel An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia 2013 Osteopathic family physician , Vol. 5,No.2 Elsevier p. 79-85
Article (Sami2013) Sami, S. S. / Ragunath, K. The Los Angeles classification of gastroesophageal reflux disease 2013 Video journal and Encyclopedia of GI Endoscopy , Vol. 1, No. 1Elsevier p. 103-104
P. Suresh Kumar et al. Formulation and Evaluation of Baclofen Extended Release Tablets, Indo American Journal of Pharmaceutical Research.2019:9(08)
Costa, P., & Lobo, J. M. S. (2001). Modeling and comparison of dissolution profiles. European journal of pharmaceutical sciences, 13(2), 123-133
Fujii, A., Yasui-Furukori, N., Nakagami, T., Niioka, T., Saito, M., Sato, Y., & Kaneko, S. (2009). Comparativein vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations. Drug design,development and therapy, 139-144.
Abutaleb, S., Mallah, E., Abu-Qatouseh, L., Abu-Awwad, A., Mansoor, K., Khallad, S., ... & Arafat, T. (2025). Valproic acid levels in neurodevelopmental disorders: correlation with CYP and SULT genes using LC-MS/MS. BMC neurology, 25(1), 1-9.
Prof.Parbhane M.B. et. Al., Antacid Bilayer Tablet formulation, International journal of creative thoughts, Volume 11, Issue 12 December 2023 | ISSN: 2320-2882
Article(Makwana2015) Makwana, P. K. / Patel, K. B. / Vyas, J. R. / Upadhyay, Umesh M. FORMULATION AND EVALUATION OF BILAYER TABLETS OF BACLOFEN USING SYNTHETIC POLYMERS
Journal of Drug Delivery & Therapeutics , Vol. 5, No. 3
p. 48-54
Katz, P. O., Gerson, L. B., & Vela, M. F. (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology, 108(3), 308–328.
Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J., & Jones, R. (2006). The Montreal definition and classification of gastroesophageal reflux disease. Gut, 55(6), 710–717.
3. Ciccaglione, A. F., & Marzio, L. (2003). Effect of GABA-B agonist baclofen on transient lower esophageal sphincter relaxations in humans: A meta-analysis. World Journal of Gastroenterology, 9(10), 2456–2460.
Aulton, M. E., & Taylor, K. M. G. (2018). Aulton's Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier.
Allen, L. V., Popovich, N. G., & Ansel, H. C. (2021). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (12th ed.). Wolters Kluwer.
Tripathi, K. D. (2019). Essentials of Medical Pharmacology (8th ed.). Jaypee Brothers Medical Publishers.
N Abduljabbar, Hana / M Badr-Eldin, Shaimaa / M Aldawsari, Hibah Gastroretentive ranitidine hydrochloride tablets with combined floating and bioadhesive properties: Factorial design analysis, in vitro evaluation and in vivo abdominal X-ray imaging 2015 Current Drug Delivery , Vol. 12, No. 5 Bentham Science Publishers
p. 578-590
Article (PatilBhushan2022) Patil Bhushan, R. / Patel Janki, B. A COMPREHENSIVE REVIEW ON TECHNOLOGICAL ASPECTS IN BILAYER TABLET MANUFACTURING 2022
Indian Pharmacopoeia 2018, Volume-2
Indian Pharmacopoeia 2018, Volume-3
Swati et al., FORMULATION AND EVALUATION OF BILAYER TABLET: A REVIEW.
Sandeep Rajan Kolli, K.MohiniKalyani, B.Lakshmi, K.Vineela, Novel UV Spectrophotometric Determination of Rabeprazole Sodium In Bulk and Pharmaceutical Dosage Forms, Asian Journal of Pharmaceutical Technology & Innovation, 02 (08); 2014.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
